Clinical efficacy and safety of donepezil in the treatment of Alzheimer&amp;rsquo;s disease in Chinese patients

Zhang, Nan; Gordon, M.S.

doi:10.2147/cia.s159920

Cited by 51 publications

(23 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Donepezil is primarily used in clinical applications as a cholinesterase inhibitor; donepezil also maintains neuroprotective effects by reducing the neurotoxicity of Aβ, reducing the neurotoxicity of glutamate, and inhibiting excitotoxic injury (Zhang & Gordon, ).…”

Section: Resultsmentioning

confidence: 99%

Potential synaptic plasticity‐based Shenzhiling oral liquid for a SAD Mouse Model

Wang

Chen

et al. 2019

Brain and Behavior

View full text Add to dashboard Cite

Background Synaptic plasticity is the basis of memory formation. The pathological manifestations of abnormal glucose metabolism in the nervous system of sporadic Alzheimer's disease (SAD) may affect synaptic plasticity, thus causing memory damage. As a traditional Chinese medicine compound preparation, the mechanism by which Shenzhiling (SZL) oral liquid can alleviate the cognitive impairment of SAD by improving synaptic plasticity remains unclear. Objective: This article mainly discusses whether SZL can exert a protective synaptic effect as mediated by glutamate receptors and glycogen synthesis kinase 3β (GSK3β); further, it discusses whether SZL can improve cognitive function in SAD. Methods C57BL/6 mice were used as a SAD model after injection with streptozotocin (STZ) into the bilateral lateral ventricles; mice of the same background were injected with artificial cerebrospinal fluid into bilateral ventricles and were used as a control group. After 3 months of exposure to the intervention, the step‐down test was carried out. Western blot was used to detect the levels of NMDAR2B, p‐NMDAR2B, mGlu5, GSK3β, and p‐GSK3β in the hippocampus of mice. Immunohistochemical analysis was used to observe the number of GSK3β‐positive cells in the CA1 region of mouse hippocampus. Results The memory retention ability of mice was significantly improved after 3 months of SZL treatment, and the expression levels of NMDAR2B, mGlu5, and GSK3β were significantly changed. Conclusion Shenzhiling provides a potential for the treatment for SAD with traditional Chinese medicine.

show abstract

Section: Resultsmentioning

confidence: 99%

Potential synaptic plasticity‐based Shenzhiling oral liquid for a SAD Mouse Model

Wang

Chen

et al. 2019

Brain and Behavior

View full text Add to dashboard Cite

show abstract

“…These findings are in agreement with those of studies, which have revealed that the major components of YQF extract (i.e., ginsenoside Rg1, Rb1, berberine, and ligustilide) exert antidementia effects in various animal models of the following mechanisms: induction alpha-processing of APP and Klotho and potential Ab clearance, increasing the expressions of neurotrophic factors and signaling (Kuang et al, 2017;Cao et al, 2018;Yang et al, 2018). Donepezil, an acetylcholinesterase inhibitor (AChEI), has been widely used to treat Alzheimer's disease (AD) in China (Zhang and Gordon, 2018), so we used donepezil as the positive control in the present study. Our findings demonstrated that treatment with YQF extract also significantly increased the total number of neurons in the hippocampal CA1 region, enhanced the Ach level, and decreased the b-AP level.…”

Section: Discussionmentioning

confidence: 99%

Yizhi Qingxin Formula Extract Ameliorates Cognitive Decline in Aged Rats via the Brain-Derived Neurotrophic Factor/Tropomyosin Receptor Kinase B Pathway

Cao

Wang

et al. 2020

Front. Pharmacol.

View full text Add to dashboard Cite

Cognitive impairment and decline in old age are primarily driven by the accumulation of agerelated neuropathologies, and old age is thus the primary risk factor for neurodegenerative diseases such as AD. Here, we investigated the effects of Yizhi Qingxin formula (YQF) extract on cognitive impairment in aged rats and determine the role of the brain-derived neurotrophic factor (BDNF)/tropomyosin receptor kinase B (TrkB) pathway underlying the neuroprotective effects of the YQF extract. Fifty male Wistar rats were randomly divided into five groups: Control group, Model group, Donepezil group, and YQF extract groups (treatment with YQF extract at two different doses). After treatment with YQF extract for 8 weeks, learning and cognitive abilities were assessed using the Morris water maze. Morphological changes in the hippocampus were observed using hematoxylin-eosin. Activated microglia and astrocytes were assessed using immunohistochemistry. Expressions of proteins and genes were examined using western blotting and real-time PCR. The results revealed that oral treatment with YQF extract dramatically improved spatial learning and memory ability and ameliorated histopathological and morphological characteristics in aged rats. YQF extract significantly increased acetylcholine and interleukin (IL)-10 levels but markedly decreased amyloid-b peptide, tumor necrosis factor alpha (TNFa), IL-2, and IL-6 levels. In addition, it inhibited the excessive activation of microglia and astrocytes, downregulated the expressions of TNFa and IL-2, and upregulated nerve growth factor, BDNF, and TrkB expressions. Furthermore, hippocampal extracellular signal-related kinase (Erk) and protein kinase B (Akt), the upstream signaling of BDNF/ TrkB, were also activated by treatment with YQF extract. Our findings indicate that YQF extract activates the BDNF/TrkB pathway through the upregulation of Erk and Akt signaling, and the activated signaling pathway might contribute to the protective effects of YQF extract on cognitive impairment in aged rats.

show abstract

“…There is now increasing evidence on a wide range of interventions for dementia undertaken in Chinese populations. A few reviews have been published, focusing on specific interventions and subtypes of dementia, such as the efficacy of donepezil in Chinese with Alzheimer’s disease, 18 Chinese herbal medicine as adjunctive therapy for vascular dementia 19 and traditional Chinese mind-body exercise (baduanjin) in older adults with mild cognitive impairment (MCI). 20 Growing evidence also suggests that the therapeutic response to dementia intervention (eg, donepezil) might differ between Chinese and Western populations due to pharmacogenetic factors, 18 21 thus emphasising the need for more accurate evaluations of interventions tailored to Chinese populations.…”

Section: Introductionmentioning

confidence: 99%

Effectiveness of interventions for people living with dementia and their carers in Chinese communities: protocol for a systematic review and meta-analysis of randomised controlled trials

et al. 2021

View full text Add to dashboard Cite

IntroductionAs the largest and most rapidly ageing population, Chinese people are now the major driver of the continued growth in dementia prevalence globally. The need for evidence-based interventions in Chinese communities is urgent. Although a wide range of pharmacological and non-pharmacological interventions for dementia have been trialled in Chinese populations, the evidence has not been systematically synthesised. This systematic review and meta-analysis aims to map out the interventions for people living with dementia and their carers in Chinese communities worldwide and compare the effectiveness of these interventions.Methods and analysisThis protocol followed the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols checklist. We will search Chinese (China National Knowledge Infrastructure, WanFang DATA) and English bibliographical databases (MEDLINE, EMBASE, PsycINFO, CINAHL Plus, Global Health, WHO Global Index Medicus, Virtual Health Library, Cochrane CENTRAL, Social Care Online, BASE, MODelling Outcome and cost impacts of interventions for DEMentia (MODEM) Toolkit, Cochrane Database of Systematic Reviews), complemented by hand searching of reference lists. We will include studies evaluating the effectiveness of interventions for dementia or mild cognitive impairment in Chinese populations, using a randomised controlled trial design, and published between January 2008 and June 2020. We will use a standardised form to extract data and Version 2 of the Cochrane risk-of-bias tool for randomised trials to assess the risk of bias of the included studies. Collected data will be fully interpreted with narrative synthesis and analysed using pairwise and network meta-analyses to pool intervention effects where sufficient information is available. We will perform subgroup analysis and meta-regression to explore potential reasons for heterogeneity.Ethics and disseminationNo formal ethics approval is required for this protocol. The findings will facilitate the development of studies on interventions for dementia and timely inform dementia policymaking and practice. Planned dissemination channels include peer-reviewed publications, conference presentations, public events and websites.PROSPERO registration numberCRD42019134135.

show abstract

Clinical efficacy and safety of donepezil in the treatment of Alzheimer’s disease in Chinese patients

Cited by 51 publications

References 48 publications

Potential synaptic plasticity‐based Shenzhiling oral liquid for a SAD Mouse Model

Potential synaptic plasticity‐based Shenzhiling oral liquid for a SAD Mouse Model

Yizhi Qingxin Formula Extract Ameliorates Cognitive Decline in Aged Rats via the Brain-Derived Neurotrophic Factor/Tropomyosin Receptor Kinase B Pathway

Effectiveness of interventions for people living with dementia and their carers in Chinese communities: protocol for a systematic review and meta-analysis of randomised controlled trials

Contact Info

Product

Resources

About